In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects - PubMed (original) (raw)
. 2004 Aug 15;104(4):1145-50.
doi: 10.1182/blood-2004-01-0388. Epub 2004 May 4.
Affiliations
- PMID: 15126317
- DOI: 10.1182/blood-2004-01-0388
Free article
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Mark Levis et al. Blood. 2004.
Free article
Abstract
Patients with acute myeloid leukemia (AML) harboring internal tandem duplication mutations of the FLT3 receptor (FLT3/ITD mutations) have a poor prognosis compared to patients lacking such mutations. Incorporation of FLT3 inhibitors into existing chemotherapeutic regimens has the potential to improve clinical outcomes in this high-risk group of patients. CEP-701, an indolocarbazole-derived selective FLT3 inhibitor, potently induces apoptosis in FLT3/ITD-expressing cell lines and primary leukemic blasts. We conducted a series of in vitro cytotoxicity experiments combining CEP-701 with chemotherapy using the FLT3/ITD-expressing cell lines MV4-11 and BaF3/ITD as well as a primary blast sample from a patient with AML harboring a FLT3/ITD mutation. CEP-701 induced cytotoxicity in a synergistic fashion with cytarabine, daunorubicin, mitoxantrone, or etoposide if used simultaneously or immediately following exposure to the chemotherapeutic agent. In contrast, the combination of pretreatment with CEP-701 followed by chemotherapy was generally antagonistic, particularly with the more cell cycle-dependent agents such as cytarabine. This effect appears to be due to CEP-701 causing cell cycle arrest. We conclude that in FLT3/ITD-expressing leukemia cells, CEP-701 is synergistic with standard AML chemotherapeutic agents, but only if used simultaneously with or immediately following the chemotherapy. These results should be considered when designing trials combining chemotherapy with each of the FLT3 inhibitors currently in clinical development.
Similar articles
- A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 - A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 - Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Clinical Trial. - [Current and new therapeutic strategies in acute myeloid leukemia].
Naito K, Ohnishi K. Naito K, et al. Gan To Kagaku Ryoho. 2005 Mar;32(3):292-6. Gan To Kagaku Ryoho. 2005. PMID: 15791811 Review. Japanese. - FLT3 mutations: biology and treatment.
Small D. Small D. Hematology Am Soc Hematol Educ Program. 2006:178-84. doi: 10.1182/asheducation-2006.1.178. Hematology Am Soc Hematol Educ Program. 2006. PMID: 17124058 Review.
Cited by
- The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Fiorentini A, Capelli D, Saraceni F, Menotti D, Poloni A, Olivieri A. Fiorentini A, et al. Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24. Oncol Ther. 2020. PMID: 32700072 Free PMC article. Review. - Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies.
Nong T, Mehra S, Taylor J. Nong T, et al. Cells. 2024 Aug 21;13(16):1392. doi: 10.3390/cells13161392. Cells. 2024. PMID: 39195279 Free PMC article. Review. - Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
Kiyoi H, Naoe T. Kiyoi H, et al. Int J Hematol. 2006 May;83(4):301-8. doi: 10.1532/IJH97.06071. Int J Hematol. 2006. PMID: 16757428 Review. - FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M, Baer MR. Larrosa-Garcia M, et al. Mol Cancer Ther. 2017 Jun;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876. Mol Cancer Ther. 2017. PMID: 28576946 Free PMC article. Review. - Establishment of xenotransplantation model of human CN-AML with FLT3-ITD (mut) /NPM1 (-) in NOD/SCID mice.
Shang Z, Wang J, Wang D, Xiao M, Li TJ, Wang N, Huang L, Zhou JF. Shang Z, et al. J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33(3):329-334. doi: 10.1007/s11596-013-1119-6. Epub 2013 Jun 17. J Huazhong Univ Sci Technolog Med Sci. 2013. PMID: 23771655
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous